Trademark Overview
On Monday, May 4, 2026, a trademark application was filed for ONXELDAR with the United States Patent and Trademark Office. The USPTO has given the ONXELDAR trademark a serial number of 99802839. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, May 4, 2026. This trademark is owned by Celgene Corporation. The ONXELDAR trademark is filed in the Pharmaceutical Products category with the following description:
Antivirals; Antibodies for medical purposes; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, autoimmune diseases, solid organ transplant rejection, autoinflammatory diseases, blood diseases, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, Alzheimer’s disease, autism spectrum disorder, and musculoskeletal and skin diseases; Biological preparations for the treatment of cancer
